Clinical predictors of BRCA1/2 P/LP variants for high-risk breast cancer patients in China: HBRCA-risk prediction
By
Wei Gu
Chengyin Xu
Jinzhen Fu
Huijun Lei
Najeeb Ullah Khan
Ruijiao Lei
Xukai Chen
Xiao-jia Wang
Tianhui Chen
June 2, 2026
Clinical Report: Identifying Clinical Indicators of BRCA1/2 Pathogenic Variants
Overview {'add': 'Discuss the broader implications of the predictive model for patient outcomes.'}
Background {'add': 'Provide examples of the limitations faced by predictive tools in China.'}
Data Highlights {'format': 'Ensure consistency in table presentation and add units where necessary.'}
Key Findings {'add': 'Include implications of older age on BRCA1/2 variant risk.'}
Clinical Implications {'expand': 'Detail how the model can enhance patient management strategies.'}
Conclusion {'reiterate': "Emphasize the study's relevance to current clinical practices and literature."}
Related Resources & Content
Kalogerakos, A., Springer, 2021 -- Addressing the Management of BRCA Mutation Carriers in China: A Response Huang, Y., Springer, 2021 -- Evaluating the Precision of BRCA1/2 Mutation Prediction Models Across Various Ethnic and Gender Groups ASCO Post, 2025 -- Improvements in BRCA2 Testing Could Enhance Cancer Risk Assessment, Patient Care ASCO Post, 2022 -- Assessment of Cancer Risk Profile for Germline BRCA1 and BRCA2 Pathogenic Variants NCCN Guidelines Insights, 2026 -- Genetic/Familial High-Risk Assessment NCCN Guidelines Insights on Genetic/Familial High-Risk Assessment Olaparib Yields Long-Term Efficacy in BRCA+ HER2-Negative Breast Cancer Consensus Statements for BRCA-Associated Breast Cancer in Asia-Pacific Global prevalence and ethnic variation of pathogenic BRCA1/2 variants in breast cancer: a systematic review and meta-analysis - PMC
